P21-activated kinase 5 plays essential roles in the proliferation and tumorigenicity of human hepatocellular carcinoma

Acta Pharmacologica Sinica

Volumn 35, Issue 1, 2014, Pages 82-88

  Fang, Zhe Ping ^a   Jiang, Bei Ge ^b   Gu, Xue Feng ^c   Zhao, Bin ^c   Ge, Rui Liang ^b   Zhang, Fa Biao ^a  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

beta catenin; cell cycle arrest; cell proliferation; Cyclin D1; gene silencing; HepG2 cell; human hepatocellular carcinoma; P21 activated kinase 5 (PAK5); tumorigenesis

Indexed keywords

BETA CATENIN; CYCLIN D1; P21 ACTIVATED KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; MTT ASSAY; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; P21-ACTIVATED KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891795716     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.31     Document Type: Article

References (35)

1. Bagrodia S, Cerione RA. Pak to the future. Trends Cell Biol 1999; 9: 350-5. (Pubitemid 29447715)
2. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem 2003; 72: 743-81. (Pubitemid 36930459)
3. Sells MA, Chernoff J. Emerging from the Pak: the p21-activated protein kinase family. Trends Cell Biol 1997; 7: 162-7. (Pubitemid 27135576)
4. Jaffer ZM, Chernoff J. p21-activated kinases: three more join the Pak. Int J Biochem Cell B 2002; 34: 713-7. (Pubitemid 34304160)
5. Pandey A, Dan I, Kristiansen TZ, Watanabe NM, Voldby J, Kajikawa E, et al. Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain. Oncogene 2002; 21: 3939-48. (Pubitemid 34620863)
6. Cotteret S, Jaffer ZM, Beeser A, Chernoff J. p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol 2003; 23: 5526-39. (Pubitemid 36951321)
7. Wu X, Frost JA. Multiple Rho proteins regulate the subcellular targeting of PAK5. Biochem Bioph Res Commun 2006; 351: 328-35. (Pubitemid 44666693)
8. Cotteret S, Chernoff J. Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic properties. Mol Cell Biol 2006; 26: 3215-30.
9. Dan C, Nath N, Liberto M, Minden A. PAK5, a new brain-specific kinase, promotes neurite outgrowth in N1E-115 cells. Mol Cell Biol 2002; 22: 567-77. (Pubitemid 34027501)
10. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006; 98: 671-80. (Pubitemid 43821785)
11. Car ter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO, et al. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004; 10: 3448-56. (Pubitemid 38685452)
12. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003; 163: 985-92. (Pubitemid 37040134)
13. Mahlamaki EH, Kauraniemi P, Monni O, Wolf M, Hautaniemi S, Kallioniemi A. High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia 2004; 6: 432-9. (Pubitemid 39411079)
14. Davila M, Frost AR, Grizzle WE, Chakrabarti R. LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem 2003; 278: 36868-75. (Pubitemid 37140021)
15. Gong W, An Z, Wang Y, Pan X, Fang W, Jiang B, et al. P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration. Int J Can 2009; 125: 548-55.
16. Wang X, Gong W, Qing H, Geng Y, Wang X, Zhang Y, et al. p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells. Tumour Biol 2010; 31: 575-82.
17. Giroux V, Iovanna JL, Garcia S, Dagorn JC. Combined inhibition of PAK7, MAP3K7 and CK2alpha kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts. Cancer Gene Ther 2009; 16: 731-40.
18. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Can 2010; 127: 2893-917.
19. Coleman JE, Huentelman MJ, Kasparov S, Metcalfe BL, Paton JF, Katovich MJ, et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003; 12: 221-8. (Pubitemid 37139701)
20. Perez-Martinez FC, Alonso V, Sarasa JL, Nam-Cha SG, Vela-Navarrete R, Manzarbeitia F, et al. Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-?B ligand. J Clin Pathol 2007; 60: 290-4. (Pubitemid 46447745)
21. Joo M, Kang YK, Kim MR, Lee HK, Jang JJ. Cyclin D1 overexpression in hepatocellular carcinoma. Liver 2001; 21: 89-95. (Pubitemid 32409535)
22. Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL, Apte U. Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther 2011; 338: 12-21.
23. Dahmani R, Just PA, Perret C. The Wnt/beta-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gas 2011; 35: 709-13.
24. Zekri AR, Bahnassy AA, Alam El-Din HM, Morsy HM, Shaarawy S, Moharram NZ, et al. Serum levels of beta-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma. Oncol Rep 2011; 26: 825-31.
25. Xu JM, Wen JM, Zhang M, Lu GL, Wu LZ, Wang WS. A study of gene amplification and expression of cyclin D1 in hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi 2004; 33: 26-30.
26. Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 2001; 61: 5389-95. (Pubitemid 32694916)
27. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41. (Pubitemid 23098782)
28. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
29. Eswaran J, Soundararajan M, Knapp S. Targeting group II PAKs in cancer and metastasis. Cancer Metast Rev 2009; 28: 209-17.
30. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006; 6: 459-71.
31. Wells CM, Jones GE. The emerging importance of group II PAKs. Biochem J 2010; 425: 465-73.
32. Yang JX, Han YJ, Zheng H, Luo RC. Expression of PAK4 in breast cancer and benign breast pathological changes. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30: 981-3.
33. Wells CM, Whale AD, Parsons M, Masters JR, Jones GE. PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J Cell Sci 2010; 123: 1663-73.
34. Li X, Ke Q, Li Y, Liu F, Zhu G, Li F. DGCR6L, a novel PAK4 interaction protein, regulates PAK4-mediated migration of human gastric cancer cell via LIMK1. Int J Biochem Cell Biol 2010; 42: 70-9.
35. Kaur R, Yuan X, Lu ML, Balk SP. Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. Prostate 2008; 68: 1510-6.